Clinical trial · Interventional
Evaluation of SR 31747A Versus Placebo in Androgen-Independent Non Metastatic Prostate Cancer
Evaluation of Two Doses of SR31747A (75 mg and 125 mg) in Non-Metastatic Androgen-Independent Prostate Cancer. Randomized, Double-Blind, Placebo Controlled Phase II Study
NCT00174863CI-TRIAL-00001851ODYSSEYcompletedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To evaluate the efficacy of SR31747 given at 75 or 125mg per day versus placebo in androgen prostate cancer patient without distant metastases with Time to Clinical progression as main objective and PSA parameters, Tumor response, survival , safety,Tumor-related symptoms deterioration Quality of Life, PK analysis as secondary objectives
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostatic Neoplasm | Prostate Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| SR31747A | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Time To Clinical Progression assessed by every 4 weeks clinical examination and every 12 weeks radiological examinations (Thoraco-abdominopelvic CT scan ; Bone scan ± centered Bone X-rays, MRI)
Secondary outcomes (2)
- measure
- Every 4 weeks: Clinical examination (safety, Tumor related symptoms deterioration), PSA level determination (PSA endpoints), EuroQoL instrument (Quality of Life), Laboratory tests (Hematology, Biochemistry), one PK sample
- measure
- Every 12 weeks: radiological examinations (tumor response),
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Prior confirmed histological diagnosis of prostatic carcinoma. * Rising PSA while receiving hormonal therapy or after surgical castration defined as 2 sequential increases above a previous lowest reference value within the past 12 months; PSA must be at least 4ng/ml at the time of study entry. * No distant metastases as evidenced by bone scan (+ or - centered X-Ray or MRI), and spiral thoracoabdominopelvic CT scan. * Effective castration throughout the study. Any prior anti-androgen therapy should be stopped with documented continued elevation of PSA 4 weeks after the cessation of flutamide (6 weeks for bicalutamide). * Serum testosterone levels \< 50ng/dL at the time of progression and throughout the study. * Age \> or = to 18 years. * Extensive metabolizer by CYP2D6 genotyping. * Karnofsky Performance Status \> or = to 70% and life expectancy \> 6 months. * Adequate hematological, renal and liver function. * Signed written informed consent Exclusion Criteria: * Poor metabolizers by CYP2D6 genotyping. * Prior palliative radiotherapy or any prior chemotherapy or experimental therapy. * More than one line of any prior anticancer treatment with estrogen (estrogen or estramustine) if discontinued at least 4 weeks before study entry. * Concomitant administration of biphosphonate or chronic corticosteroids. * Presence of progressive symptoms not adequately controlled with non opioid medications * Concomitant use of medications known to be cytochrome P450 2D6 inhibitors as listed in protocol appendice * Previous malignancies except if there has been a disease-free interval of at least 5 years and except curatively treated non-melanoma skin cancer * Other serious illness or medical condition, which would not permit the patient to be managed according to the protocol.
References
Publications (0)
Data not yet available
No reference posted for this study.